ArticleFrontiers in oncology2025
Clinical outcomes of xenogeneic acellular dermal matrix combined with full-thickness skin graft in the eyelid reconstruction following the excision of eyelid malignant tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extended Superolateral Periosteal Flap for Single-Stage Total Lower Eyelid Reconstruction.Archives of plastic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigates the clinical efficacy of using the xenogeneic acellular dermal matrix (XADM) combined with full-thickness skin graft (FTSG) to reconstruct full-thickness eyelid defects following the excision of large malignant tumors. Methods: This single-center retrospective observational study analyzed 21 patients who received XADM combined with FTSG for full-thickness eyelid defects reconstruction following tumor resection at our hospital between January 2020 and September 2022. The study was reported according to the STROBE statement reporting guidelines. The cases included 13 basal cell carcinomas, one meibomian gland carcinoma, and seven squamous cell carcinomas. In the first-stage surgery, XADM combined with a FTSG was used to reconstruct the full-thickness eyelid defect. In the postoperative, a pressure dressing was applied for 5 days removing stitches at 2 weeks. Repair outcomes were assessed at 1, 3, and 6 months postoperatively. At the 6 months postoperative follow-up, second-stage surgery was performed to separate the upper and lower eyelids, restoring normal eyelid anatomy and function. Results: At 2 weeks postoperatively, all graft marginal sutures were well-aligned, and no graft necrosis was observed after sutures were removed. No complications were found during the follow-up at 1 and 3 months postoperatively. At 6 months postoperatively, separation of upper and lower eyelid adhesions was performed. Slit-lamp examination post eyelid separation surgery reveals the overall healing outcome was satisfactory, with no significant inflammatory response or rejection observed. The overall healing outcome was satisfactory, with no significant inflammatory response or rejection observed. All 21 patients recovered well postoperatively. No significant complications were observed in any patient, with only one patient exhibiting mild lagophthalmos. Conclusion: In full-thickness eyelid reconstruction following the excision of eyelid malignant tumors, using XADM for reconstructing the posterior lamella and conjunctiva, combined with FTSG for repairing the eyelid skin and soft tissue, is a recommended approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.